Amendment No. 3 to Grant Agreement between Bill & Melinda Gates Foundation and Dare Bioscience, Inc.

Contract Categories: Business Finance › Modification Agreements
Summary

This amendment updates the grant agreement between the Bill & Melinda Gates Foundation and Dare Bioscience, Inc., originally effective June 30, 2021. The main change is a revised payment and reporting schedule for the grant, with new dates and amounts specified. The total grant amount may be up to $48,945,928. All other terms of the original agreement remain unchanged, and in case of any conflict, this amendment takes precedence. No signatures are required for this amendment to be effective.

Read More Arrow
EX-10.3 5 exhibit103amendmentno3gate.htm EX-10.3 Document

Exhibit 10.3
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN THIS EXHIBIT, [**] INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED.

AMENDMENT 3
to
GRANT AGREEMENT
Investment ID INV-026060
AMENDMENT SUMMARY PAGE
AMENDMENT INFORMATION
Agreement to be Amended:
Grant agreement between the Bill & Melinda Gates Foundation and Dare Bioscience, Inc., effective June 30, 2021, as amended, and bearing Investment ID INV-026060
Amendment Purpose:
Payment & Reporting Schedule Change
“Amendment Date”:
Date of this email
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the Amendment Date. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
REPORTING & PAYMENT SCHEDULE
This Amendment notifies You that the reporting and/or payment schedule for Your grant has changed. Your Reporting & Payment Schedule is deleted and replaced with the following:
REPORTING & PAYMENT SCHEDULE
Investment Period
Target, Milestone, or Reporting Deliverable
Due By
Payment Date
Payment Amount (U.S.$)
Countersigned Agreement
July 2021
$11,453,099.00
[**]
[**]
[**]July 2022$7,960,608.00
[**]
[**]
[**]
[**][**]
[**]
[**][**]
[**]
[**]


Investment ID INV-026060                    1 of 3                    Version: August 2022

[**]
November
2022
$4,436,204.00
[**]
[**]
[**][**]
September
2023
$4,500,000.00
[**]
[**]
[**]
[**]
[**]
[**][**]
[**]
[**][**][**]
Scheduled:
April 2024
$1,000,000.00
[**]
[**]
[**]
[**]
[**]
[**]
[**][**]
[**]
[**]
[**]
[**]
[**]
[**][**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**][**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**]
[**][**]
[**][**]
[**]
[**]
[**]
[**]


Investment ID INV-026060                    2 of 3                    Version: August 2022

[**]
[**]
[**]
[**]
[**]
[**]
[**][**]
Amended Total Grant Amount
Up to $48,945,928.00
As provided in the Agreement, signatures are not required.


Investment ID INV-026060                    3 of 3                    Version: August 2022